A_prospective_randomized_trial_of_adjuvant_chemotherapy_with_bolus_versus_continuous_infusion_of_doxorubicin_in_patients_with_high-grade_extremity_soft_tissue_sarcoma_and_an_analysis_of_prognostic_factors._A_prospective_randomized_trial_was_conducted_to_compare_the_cardiotoxic_and_therapeutic_effects_of_doxorubicin_(60_mg/m2_every_3_to_4_weeks)_administered_by_bolus_or_72-hour_continuous_infusion_as_adjuvant_chemotherapy_in_82_eligible_patients_after_resection_of_high-grade_soft_tissue_sarcoma_of_the_extremity_or_superficial_trunk._Cardiac_toxicity,_defined_as_a_10%_or_greater_decrease_in_left_ventricular_ejection_fraction_as_assessed_by_radionuclide_cineangiography,_was_evaluated_in_69_patients._Cardiotoxicity_was_seen_in_61%_of_patients_in_the_bolus_treatment_arm_with_the_median_doxorubicin_dose_of_420_mg/m2._Among_patients_who_received_continuous_infusion,_42%_had_cardiotoxicity_with_a_median_dose_of_540_mg/m2._The_rate_of_cardiotoxicity_as_a_function_of_the_cumulative_dose_of_doxorubicin_was_significantly_higher_in_the_bolus_treatment_arm_(P_=_0.0017)._Two_patients_in_each_group_had_clinical_congestive_heart_failure,_with_one_cardiac_death_occurring_in_each._There_was_a_trend_toward_a_lower_rate_of_metastasis_(P_=_0.19)_and_a_significantly_lower_rate_of_death_of_disease_(P_=_0.036)_for_patients_treated_with_the_bolus_dose._Cox_model_analysis_identified_three_unfavorable_characteristics_for_the_rate_of_developing_a_distant_metastasis:_blood_transfusion_within_24_hours_of_operation_(P_less_than_0.00001),_tumor_deep_to_the_fascia_and_5_cm_or_more_in_size_(P_=_0.0043),_and_a_histologic_subtype_other_than_liposarcoma_(P_=_0.0002)._The_unfavorable_effect_of_continuous_infusion_was_not_selected_in_the_model_(P_=_0.16)._Adjuvant_chemotherapy_for_patients_with_soft_tissue_sarcoma_is_investigational._Furthermore,_the_impact_of_perioperative_blood_transfusion_merits_further_study.